ZIVO Bioscience, Inc.
Moat Score — ZIVO Bioscience, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Zivo holds proprietary algae and bacterial strains and related cultivation/extraction know-how developed over many years and 23 clinical trials, which is a real intangible asset, but none of its therapeutic candidates has reached regulatory approval or a signed commercial license, so the IP's monetizable value remains unproven. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Zivo has no cost advantage; it relies on a third-party contract manufacturer (Alimenta Algae in Peru) for its only commercial product and has no production scale, purchasing power, or process efficiency edge over far larger animal-health and ingredient companies. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With Zivolife sales volumes described by the company itself as 'relatively low' and no commercialized therapeutic product, Zivo has no demonstrated ability to set or hold prices against established competitors like Zoetis or Elanco. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Zivo's business (biological IP licensing and a direct-to-consumer nutrition product) has no network effect; the value of its products does not increase as more users or partners adopt them. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | If a therapeutic candidate were eventually licensed, a partner that built regulatory filings and manufacturing processes around Zivo's proprietary strain could face some switching cost, but this is purely hypothetical today since no such license yet exists, and the nutrition product carries no consumer switching cost at all. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Zivo operates in large, multi-player markets (animal health, human nutrition supplements) that are not naturally limited to one or two efficient-scale incumbents, and it is a minor participant rather than a scale-advantaged one in any of them. |